Latest Regulatory Milestones News

International Graphite Limited has secured development approval for its Collie graphite processing facility, marking a significant step toward integrated graphite production in Western Australia.

Telix Pharmaceuticals confirms completion of Part 1 enrolment in its ProstACT Phase 3 trial for prostate cancer, with safety data supporting progression to Part 2 and regulatory approvals secured across multiple countries.

Neurotech International has locked in $4 million through a share placement to advance its promising paediatric neurological drug, NTI164. The raise, supported by both new and existing investors including company directors, aims to fund critical clinical and regulatory milestones.

Audalia Resources is set to raise $540,000 through a share placement to fund critical development stages of its Medcalf Project and bolster working capital.

Lunnon Metals has secured critical mining proposal approval for its Lady Herial gold deposit, moving the project closer to production under a binding ore purchase deal with St Ives Gold Mining.

Javelin Minerals has lodged its Mining Proposal for the Eureka Gold Project, setting the stage for mining to commence in mid-2026 and first cashflow by Q3. Fully funded and partnered with MEGA Resources, the project is on track to unlock value in Western Australia’s prolific goldfields.

4DMedical has gained Canadian regulatory approval for its innovative CT – VQ™ ventilation-perfusion imaging technology, enabling immediate commercial rollout through Philips and expanding its North American footprint.

Western Yilgarn NL has secured critical access rights for its Cardea 2 Bauxite Project, enabling immediate fieldwork, while simultaneously initiating ground exploration at the Ida Holmes Junction Project targeting key critical minerals.

Diatreme Resources has submitted the Draft Environmental Impact Statement for its Northern Silica Project, marking a significant step toward regulatory approval and highlighting its potential to boost regional economies and support global solar energy growth.

Prescient Therapeutics has secured European authorization to initiate a Phase 2a clinical trial of its novel cancer drug PTX-100 for relapsed/refractory Cutaneous T-cell Lymphoma, enabling trial site activation in Italy.

Orthocell has lodged a regulatory application to distribute its nerve repair product Remplir™ across the EU and UK, aiming to tap into a $750 million market with approval expected by Q3 2026.

Neuren Pharmaceuticals’ partner Acadia secures FDA approval for DAYBUE STIX, a new powder formulation of trofinetide offering greater flexibility for Rett syndrome patients. This milestone expands treatment options and sets the stage for increased royalty revenue in 2026.